GSK and Ionis Pharmaceuticals stand to gain significant profits as their experimental hepatitis B drug, bepirovirsen, moves through fast-track review by the U.S. Food and Drug Administration. This first-of-its-kind drug, developed by these corporations, has shown a "functional cure" in approximately 20% of patients, allowing them to cease treatment without detectable signs of the dangerous liver virus. The FDA's decision is expected in October, with regulators in Japan, China, and Europe also considering approval, paving the way for a new commodity in the global health market.
The drug, nicknamed "bepi," achieved this outcome in about 1 in 5 patients across two international studies. For these individuals, the virus was reduced to levels low enough for their immune systems to keep it in check. This "functional cure" meant the virus remained undetectable for six months after patients stopped all treatment, a result not observed in those receiving dummy shots.
Chronic hepatitis B is a severe liver infection that claims approximately 1.1 million lives globally each year, often leading to liver cancer or liver failure. The disease affects more than 250 million people worldwide in its chronic form, including about 1.7 million in the U.S., representing a vast and persistent market for pharmaceutical interventions. Existing lifelong therapies, typically daily pills, aim to reduce viral levels and prevent liver damage, but a true cure has remained elusive due to the virus's ability to hide within the body, ready to rebound. These standard treatments are also noted to be difficult to adhere to or access in some countries, highlighting existing inequalities in global healthcare.
Capital's New Frontier
The development of bepirovirsen, with studies funded by GSK, positions these pharmaceutical giants to capitalize on a long-standing global health crisis. The drug functions by binding to the virus's genetic components, suppressing its replication and a key surface protein, while also stimulating the immune system, according to GSK vice president Melanie Paff. The trials involved 1,838 patients who received weekly bepirovirsen shots for six months alongside their regular pills.
The state apparatus, through regulatory bodies, is actively facilitating the market entry of this corporate product. The U.S. FDA has granted bepirovirsen a fast-track review, signaling an expedited path to market for GSK and Ionis. Regulators in Japan, China, and Europe are similarly engaged in considering the drug's approval, demonstrating a coordinated global effort to integrate this new commodity into national healthcare systems. Dr. Seng Gee Lim of the National University Health System of Singapore, who helped lead the GSK-funded studies, stated, "We have not had a treatment which has come to this level of cure," presenting the findings at a scientific meeting in Barcelona, Spain.
Partial Relief, Enduring Inequality
Despite the corporate claims of a "major step," the drug's efficacy is limited and its long-term impact remains under scrutiny. The "functional cure" was achieved by only 20% of bepirovirsen recipients, meaning the vast majority of patients in the trials did not reach this state. Furthermore, the trials explicitly excluded patients with cirrhosis, high S protein levels, or other complicating factors, indicating that the drug's benefits may be restricted to a specific, less severe patient demographic.
Dr. Anna Lok, a hepatitis expert at the University of Michigan not involved in the research, cautioned in the New England Journal of Medicine that "more study is needed to see how long that remission-like state lasts," even while acknowledging the findings "represent a major step." While GSK has tracked a small number of patients from earlier-stage studies, finding most still faring well up to three years later, this limited data does not provide a comprehensive picture of sustained remission for the broader patient population. Side effects reported included mild injection-site redness or pain and a temporary rise in enzymes indicating liver stress.
The Market for Sickness
The introduction of bepirovirsen underscores how even medical breakthroughs are framed within the logic of capital accumulation. While offering a partial solution for a segment of those afflicted, the drug's development and regulatory fast-tracking serve to open new avenues for profit for pharmaceutical corporations. The enduring challenge of access to existing therapies in many countries, coupled with the limited efficacy and specific patient exclusions of this new drug, ensures that the structural inequalities in global health, and the market for managing sickness rather than eradicating it universally, will persist.